The pharmaceutical industry constantly seeks innovative chemical building blocks to accelerate drug discovery and development. Among these essential compounds is 1-Bromo-5-Fluoropentane (CAS: 407-97-6), a halogenated alkane that offers unique reactivity for crafting complex molecular structures. As a key pharmaceutical intermediate, its availability from reliable manufacturers is crucial for research scientists and procurement specialists.

1-Bromo-5-Fluoropentane, with the molecular formula C5H10BrF, is prized for its dual functionality, allowing for selective chemical transformations. The bromine atom serves as an excellent leaving group for nucleophilic substitution reactions, while the fluorine atom can impart desirable pharmacokinetic properties, such as increased lipophilicity and metabolic stability, to potential drug candidates. Researchers often look for this compound when synthesizing fluorinated compounds intended for enhanced biological activity.

When sourcing this critical intermediate, pharmaceutical companies typically search for suppliers offering high purity, often specified as ≥99.0% assay. This level of purity ensures that the synthesized molecules are free from unwanted by-products, which is a fundamental requirement in pharmaceutical manufacturing. Furthermore, understanding the specifications, such as the physical state (colorless to pale yellow transparent liquid) and storage conditions (cool, ventilated place), is vital for maintaining product integrity.

For many R&D departments, the ability to buy 1-Bromo-5-Fluoropentane in required quantities, often from manufacturers in China known for their production capacity, is a significant advantage. Reliable suppliers not only provide the chemical but also offer essential documentation like Safety Data Sheets (SDS) and Certificates of Analysis (COA). This documentation is indispensable for regulatory compliance and safe handling in laboratory and production environments.

The demand for advanced intermediates like 1-Bromo-5-Fluoropentane underscores the importance of a robust supply chain. By partnering with reputable manufacturers and suppliers, pharmaceutical companies can ensure a consistent flow of high-quality materials, thereby accelerating their journey from laboratory synthesis to clinical trials and eventual market launch. Investing in a dependable source for this essential intermediate is a strategic step for any organization involved in cutting-edge pharmaceutical research.